
It seems that no matter how much bad press comes their way, certain pharmaceutical companies are more than happy to …

A team of researchers at the University of Maryland School of Medicine (UMSOM) has been assessing the effectiveness of a …

Sanofi has announced a recall of 12,380 syringes of its Synvisc-One product for the treatment of osteoarthritis, after it was …

Ionis Pharmaceuticals has revealed findings from its Phase 1/2a study into a treatment for Huntington’s disease and the strong data …

Andrew Lane, Executive Vice President of Established Pharmaceuticals at Abbott, discusses the key steps to be taken when reaching out …

Throughout 2017, it has emerged that the FDA has issued a record low number of warning letters to pharmaceutical firms …

Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary …

Only last month, the story broke that Teva was looking to cut away a number of employees, the rumours have …

The state of California has become the target of legal action after the lobbying group Pharmaceutical Research and Manufacturers of …

Bob Kerslake, now former chair of King’s College hospital, London, has handed in his resignation, citing the lack of long-term …

Despite us nearing the end of the year, the news has not been slowing down at all. Headlines across Europe …

When Roche announced that its combination treatment of Tecentriq, alongside its own drug Avastin and chemotherapy, successfully extended progression-free survival …

It’s only four months since Gilead completed its buy-out of Kite Pharma for $11.9 billion, but it’s already moving quickly …

Since Sanofi released further data from a six-year study which showed that the risk of a severe dengue reaction is …

Sage Therapeutics’ stock rocketed after it announced that Phase 2 results for its treatment for major depressive disorder (MDD) were …